New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2

doi:10.5306/wjco.v13.i4.276

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5397)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

396

WORD

HTML

2898

Tables (1-5)

295

Sum=3671

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

232

Download

534

Sum=766

Publishing Process of This Article

Item

Count

Browse

321

Download

639

Sum=960

Apr 24, 2022 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Apr 24, 2022; 13(4): 276-286
Published online Apr 24, 2022. doi: 10.5306/wjco.v13.i4.276

Table 5 Phase II trials with HER2 inhibitors

Drug	Molecular alteration	n	ORR%	PFS (mo)	OS (mo)
Dacomitinib[44]	HER2 mutant	26	12	NR	NR
Dacomitinib[44]	HER2-amplified	4	0	NR	NR
Neratinib + Trastuzumab[46]	HER2 mutant	52	17	4	10.2
Neratinib + Temsirolimus[46]	HER2 mutant	43	19	4	15.1
Pyrotinib[47]	HER2 mutant	60	30	6.9	14.4
Poziotinib[48]	HER2 mutant	90	28	5.5	NR
Trastuzumab emtansine[49]	IHC 2+	29	0	2.6	12.2
Trastuzumab emtansine[49]	IHC 3+	20	20	2.7	15.3
Trastuzumab deruxtecan[49]	HER-2 mutant	42	61.9	NR	NR
Trastuzumab deruxtecan[49]	IHC 2+	39	25.6	5.4	11.3
Trastuzumab deruxtecan[49]	IHC 3+	10	20	5.4	11.3

ORR: Overall response rate; PFS: Progression free survival; OS: Overall survival; NR: Not reported.

Citation: Olmedo ME, Cervera R, Cabezon-Gutierrez L, Lage Y, Corral de la Fuente E, Gómez Rueda A, Mielgo-Rubio X, Trujillo JC, Couñago F. New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2. World J Clin Oncol 2022; 13(4): 276-286
URL: https://www.wjgnet.com/2218-4333/full/v13/i4/276.htm
DOI: https://dx.doi.org/10.5306/wjco.v13.i4.276